Trivium Point Advisory’s Charles River Laboratories CRL Stock Holding History

Trivium Point Advisory’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,465	Closed	-$795K	–	190
2022 Q2	$795K	Buy	3,465 +301	+10%	+$73.5K	0.24%	124
2022 Q1	$905K	Buy	3,164 +533	+20%	+$164K	0.2%	135
2021 Q4	$991K	Sell	2,631 -227	-8%	-$88.2K	0.21%	127
2021 Q3	$1.19M	Buy	2,858 +164	+6%	+$68.1K	0.28%	112
2021 Q2	$997K	Buy	2,694 +868	+48%	+$290K	0.25%	122
2021 Q1	$529K	Buy	1,826 +334	+22%	+$92.8K	0.14%	141
2020 Q4	$393K	Buy	1,492 +292	+24%	+$69.5K	0.11%	151
2020 Q3	$272K	Buy	+1,200	New	+$249K	0.1%	147

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Trivium Point Advisory's CRL Position: Q3 2022 in Review

Trivium Point Advisory sold out of Charles River Laboratories (CRL) in Q3 2022, closing a stake of 3,465 shares — an estimated $795K sold.

Trivium Point Advisory first reported a position in CRL in Q3 2020 and held it in 8 quarters. The position peaked at $1.19M in Q3 2021. 583 funds tracked by Wall St. Rank hold CRL as of Q3 2022.

Trivium Point Advisory reported no remaining Charles River Laboratories position as of Q3 2022 after selling out during the quarter.
Trivium Point Advisory sold 3,465 Charles River Laboratories shares in Q3 2022, an estimated $795K.
Trivium Point Advisory first reported a position in Charles River Laboratories in Q3 2020 and held it in 8 quarters.
Trivium Point Advisory's Charles River Laboratories position peaked at $1.19M in Q3 2021.
583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2022.

Based on Trivium Point Advisory's 13F filing for Q3 2022, filed 9 Nov 2022.